Timebio Co., Ltd.

Time Bio Co., Ltd. was established, starting as a bio source technology company based on skin immunity and regenerative medicine.

Establishment of corporate research institute, beginning of research on umbilical cord blood-derived cells and exosomes.

GMP cleanroom construction and process verification completed, establishing a foundation for high-quality production.

Approval obtained for human-derived material research project on rheumatism from the Public Bioethics Committee.

Signed a 10-year exclusive sales agreement for ATO Standard cosmetics with Theragen Etex Co., Ltd.

Obtained permission for responsible cosmetic sales from the Ministry of Food and Drug Safety.

Obtained research facility approval for genetically modified organisms (GMO) from the Korea Centers for Disease Control and Prevention.

Venture company certification obtained and ImmunoExo™ (TEXSOME)

Registered in the International Cosmetic Ingredient Dictionary (ICID).

Participated in BIO USA 2020 (selected as KOTRA-supported company), beginning global market entry.

Obtained manufacturing license for cosmetics from the Ministry of Food and Drug Safety.

Launched ATO Standard cosmetics, obtained OTC certification from the US FDA.

Selected for the IP R&D strategic project by the Korea Intellectual Property Strategy Development Institute.

Patent registration - “Method for obtaining pre-cursor cells using cold shock and method for producing exosomes using the same”.

MOU signed with Kolmar Holdings for joint research on multi-target exosome platform technology.

Patent registration - “Pharmaceutical composition containing multifunctional exosomes derived from pre-cursor cells for prevention or treatment of dermatitis”.

Patent application - “Wound healing or wound healing-promoting composition containing exosomes derived from umbilical cord blood cells”.

Selected for Chungbuk Center for Creative Economy & Innovation IP R&D+ support project.

Confirmed efficacy of exosomes as an influenza virus vaccine adjuvant in animal experiments.

Selected for Korea Data Industry Promotion Agency Data Voucher support project.

Launch of infant skin care brand Goodyce.

Signing of sales cooperation agreement with Zion Women's Hospital.

Research on COVID-19 antiviral, wound healing agents, and cosmeceutical formulations.

(In collaboration with Korea University, etc.).

Patent registration for wound healing composition using umbilical cord blood-derived exosomes.

Development of cell-penetrating peptide coated growth factor complex composition.

Launch of hair loss prevention management “Grab N Grow”.

Designated as Gyeonggi-do Small and Strong Enterprise 1000+ (Promising SME).

Development of PLLA Adjuvant CPP Skin Booster.

Development of cell-penetrating peptide coated EGF Skin Booster.

Development of cell-penetrating peptide coated EGF + ultra-low temperature milling plant exosome complex composition.

Launch of Silk Pharm aesthetic mist.